Non-alcoholic steatohepatitis has been the subject of sustained clinical investigation across multiple research sites.

11 total trials for this combination

Showing top 10 of 11 trials

Trials

NCT ID	Title	Status	Phase
NCT00678587	Eltrombopag To Reduce The Need For Platelet Transfusion In Subjects With Chronic Liver Disease And Thrombocytopenia Undergoing Elective Invasive Procedures	TERMINATED	PHASE3
NCT03421431	A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis	COMPLETED	PHASE2
NCT02787304	Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)	TERMINATED	PHASE2
NCT03969719	A Double-blind Study to Assess 2 Doses of an Investigational Product for 16 Weeks in Participants With Non-alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus	COMPLETED	PHASE2
NCT02784444	A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH	COMPLETED	PHASE2
NCT02970942	Investigation of Efficacy and Safety of Three Dose Levels of Subcutaneous Semaglutide Once Daily Versus Placebo in Subjects With Non-alcoholic Steatohepatitis.	COMPLETED	PHASE2
NCT04378010	A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH	TERMINATED	PHASE2
NCT02686762	Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis	COMPLETED	PHASE2
NCT04171765	A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-Alcoholic Steatohepatitis	TERMINATED	PHASE2
NCT02279524	A Clinical Trial to Evaluate the Efficacy and Safety of Two Aramchol Doses Versus Placebo in Patients With NASH	COMPLETED	PHASE2

Related Pages

All Non-alcoholic steatohepatitis trials All trials in Los Angeles, United States